ArticleAnnals of hematology2025
Safety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant cyclophosphamide (PTCy) is widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem-cell transplant (HSCT). However, the optimal dosing of PTCy remains uncertain. In this case series, we evaluated intermediate-dose PTCy (25–30 mg/kg/day on Days 3 and 4) in 11 consecutive patients treated at our center between February 2023 and November 2024. Outcomes regarding engraftment were compared to our center’s historical cohort, which received standard-dose PTCy. All 11 patients achieved neutrophil engraftment, and 10 achieved platelet engraftment. Median times to neutrophil, platelet, and lymphocyte engraftment were Day 14, 17, and 21, respectively—significantly shorter than in the standard-dose group (Day 18, 23, and 40; p < 0.05 for all comparisons, Mann–Whitney U test). Complete donor chimerism was observed in all patients by Day 30. Compared to our center’s historical cohort, significantly more patients in the intermediate-dose group achieved complete donor chimerism in both total cells and T cells (p < 0.01 and p = 0.03, respectively; Fisher’s exact test). Among the 11 patients, acute GVHD occurred in 3 patients (one each of grade I, II, and III); two of those 3 developed severe chronic GVHD. One patient died from diffuse alveolar hemorrhage; the others remain alive without relapse. Intermediate-dose PTCy demonstrated favorable engraftment, high donor chimerism, and acceptable toxicity, suggesting it may be a viable option for GVHD prophylaxis, particularly in vulnerable populations such as elderly patients, those with poor performance status, comorbidities, or splenomegaly. Larger prospective studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.